attention-deficit hyperactivity disorder

Bavisant (JNJ-31001074) is a selective and orally active Human H3 receptor antagonist. Bavisant can be used in research on mechanisms of action, involving wakefulness and cognition and the treatment for ADHD.

Oxidopamine hydrobromide (6-OHDA hydrobromide) is a widely used neurotoxin and an antagonist of the neurotransmitter dopamine. It selectively destroys dopaminergic neurons, promotes COX-2 activation, induces PGE2 synthesis, and stimulates the secretion of the pro-inflammatory cytokine IL-1β. It is commonly used to establish animal models of Parkinson’s disease (PD).

Oxidopamine hydrochloride (6-Hydroxydopamine hydrochloride) is a widely used neurotoxin and an antagonist of the neurotransmitter dopamine. It selectively destroys dopaminergic neurons, promotes COX-2 activation, induces PGE2 synthesis, and stimulates the secretion of the inflammatory cytokine IL-1β. It is commonly used to establish animal models of Parkinson’s disease (PD).

MK-0249 FA is an orally active, selective and potent histamine H3 inverse agonist for the study of attention deficit, hyperactivity disorder neurodivergent and cognitive disorders in adults.

(R)-PF-04822163 is an isomer of PF-04822163. PF-04822163 is an oral, selective PDE1 inhibitor that can cross the blood-brain barrier. PF-04822163 can be used in studies about nervous system disorders such as attention deficit hyperactivity disorder (ADHD) and Parkinson’s disease.

Guanfacine hydrochloride (Intuniv) is a centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR). It is used for the research for attention-deficit hyperactivity disorder (ADHD).

Cipralisant is a selective histamine H3 receptor antagonist in vivo, and an agonist in vitro (pKi: 9.9 for histamine H3 receptor; Ki: 0.47 nM for rat histamine H3 receptor). It has the potential for the treatment of attention-deficit hyperactivity disorde

GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.

Droxidopa (L-DOPS) is an effective orally active norepinephrine precursor capable of crossing the blood-brain barrier. It can increase standing blood pressure, improve symptoms of orthostatic hypotension, and enhance standing ability. Droxidopa is commonly used in studies of neurogenic orthostatic hypotension (nOH) and alternative treatments for attention-deficit/hyperactivity disorder (ADHD).

Edivoxetine( LY2216684) is a selective norepinephrine reuptake inhibitor being developed as a treatment for attention deficit hyperactivity disorder (ADHD) and antidepressants.

SUVN-G3031 is a antagonist of histamine H3 receptor with potential for the treatment of cognitive impairment, dementia, attention deficit hyperactivity disorder, epilepsy, sleep disorders, obesity, schizophrenia, eating disorders, and pain.

Guanfacine-13C,15N3is intended for us as an internal standard for the quantification of guanfacine by GC- or LC-MS. Guanfacine is an α2-adrenergic receptor (α2-AR) agonist with Kivalues of 93, 1,380, and 3,890 nM for α2A-, α2B-, and α2C-ARs, respectively, in a radioligand binding assay.1It has EC50values of 52, 288, and 602 nM for α2A-, α2B-, and α2C-ARs, respectively, for stimulated [35S]GTPγS binding. It also binds to imidazoline receptor 1 (Ki= 19 nM in a radioligand binding assay).2Guanfacine (0.3-5 mg/kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.3It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.4Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD). 1.Jasper, J.R., Lesnick, J.D., Chang, L.K., et al.Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS bindingBiochem. Pharmacol.55(7)1035-1043(1998) 2.Nikolic, K., Filipic, S., and Agbaba, D.QSAR study of imidazoline antihypertensive drugsBioorg. Med. Chem.16(15)7134-7140(2008) 3.Scholtysik, G.Pharmacology of guanfacineBr. J. Clin. Pharmacol.10(Suppl 1)21S-24S(1980) 4.Kauser, H., Sahu, S., Kumar, S., et al.Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive declineNeuroscience254110-119(2013)

CX 717 is a positive allosteric modulator of the AMPA receptor with antidepressant-like effects and potential use in adult attention deficit hyperactivity disorder (ADHD) research [1] [2].

Droxidopa (L-DOPS) hydrochloride is a potent, orally active precursor to norepinephrine that elevates standing blood pressure, mitigates orthostatic hypotension symptoms, and enhances standing capability. It holds promise for research in neurogenic orthostatic hypotension (nOH) and alternative attention deficit hyperactivity disorder (ADHD) treatments [1] [2] [3] [4].

Edivoxetine hydrochloride is a highly effective and specialized compound used primarily as a norepinephrine reuptake inhibitor (NERI), indicated for the treatment of depressive disorder and attention-deficit hyperactivity disorder.

Ispronicline, also known as AZD3480; TC 1734; TC-0173, and RJR 1734, is a alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. Ispronicline is potentially useful for the treatment of attention-deficit hyperactivity disorder in adults.

Sofinicline benzenesulfonate (ABT 894 benzenesulfonate), a novel agonist of the nicotinic acetylcholine receptor, specifically targets the α4β2 subtype of nAChR (IC 50 =0.1 nM). This compound shows promise in enhancing cognitive functions such as attention, memory, and working memory. It is potentially useful in research pertaining to attention deficit hyperactivity disorder (ADHD).